• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review Product Image

Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review

  • Published: September 2011
  • Region: Global
  • 42 pages
  • GlobalData

FEATURED COMPANIES

  • Amgen Inc.
  • AmSurg Corp.
  • Depomed, Inc.
  • GlaxoSmithKline plc
  • IMMUNOMEDICS, INC
  • Novartis AG
  • MORE

Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review

Summary

Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company engaged in the discovery, development and marketing of albumin fusion proteins, antibodies and proprietary technologies. The company’s drugs are targeted against hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. It is also engaged in the development of oncology products and genomics-derived small molecule drugs. The company's product under pipeline are BENLYSTA , for the treatment of autoantibody-positive, raxibacumab, for the treatment of inhalation anthrax, Mapatumumab, for treatment of cancer, Darapladib, for the treatment of heart diseases, and Albiglutide, for maintaining the sugar levels. HGS is headquartered at Rockville in Maryland, the US.

Human Genome Sciences, Inc. Key Recent Developments

Aug 08, 2011: Human Genome Sciences Appoints Craig Parker As Senior Vice President, Strategy And Corporate Development
Jul 21, 2011: Human Genome Sciences Reports Total Revenue Of $24.9m For Q2 2011
May 12, 2011: Human Genome Sciences Appoints Allan Baxter To Board
Apr READ MORE >



List of Tables
List of Figures
Section 1 - About the Company
Human Genome Sciences, Inc. - Key Facts
Human Genome Sciences, Inc. - Key Employees
Human Genome Sciences, Inc. - Key Employee Biographies
Human Genome Sciences, Inc. - Major Products and Services
Human Genome Sciences, Inc. - Pharmaceutical Pipeline Products Data
Human Genome Sciences, Inc., Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Pipeline Products by Development Phase
Human Genome Sciences, Inc. - History
Human Genome Sciences, Inc. - Company Statement
Human Genome Sciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Human Genome Sciences, Inc. - Business Description
Human Genome Sciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Human Genome Sciences, Inc. - Strengths
Strength - Sturdy Research and Development Activities
Strength - Strategic Partnerships
Strength - World Class Manufacturing Facilities
Weakness - Weak Financial Performance
Weakness - Decreasing Liquidity
Weakness - Increasing Debt
Opportunity - Oncology Products
Opportunity - FDA Approval for BENLYSTA
Opportunity - Changing Demographics
Threat - Tough Credit Market Conditions
Threat - Uncertainties from Clinical R&D Activities
Threat - Stringent Government Regulations
Human Genome Sciences, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Human Genome Sciences, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 08, 2011: Human Genome Sciences Appoints Craig Parker As Senior Vice President, Strategy And Corporate Development
Jul 21, 2011: Human Genome Sciences Reports Total Revenue Of $24.9m For Q2 2011
May 12, 2011: Human Genome Sciences Appoints Allan Baxter To Board
Apr 28, 2011: Human Genome Sciences Reports Net Loss Of $131m For Q1 2011
Mar 14, 2011: Human Genome Sciences Appoints George Morrow To Board
Feb 24, 2011: Human Genome Reports Net Loss Of $87.6m For Q4 2010
Jan 21, 2011: Human Genome Appoints Greg Norden To Board
Dec 14, 2010: Human Genome Sciences Appoints Colin Goddard To Board
Dec 14, 2010: Human Genome Sciences Appoints Colin Goddard To Board
Oct 27, 2010: Human Genome Sciences Reports Net Loss Of $40.9 Million For Q3 2010
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Human Genome Sciences, Inc., Key Facts
Human Genome Sciences, Inc., Key Employees
Human Genome Sciences, Inc., Key Employee Biographies
Human Genome Sciences, Inc., Major Products and Services
Human Genome Sciences, Inc., Number of Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Number of Pipeline Products by Development Stage
Human Genome Sciences, Inc., Pipeline Products By Therapy Area and Development Phase
Human Genome Sciences, Inc., History
Human Genome Sciences, Inc., Subsidiaries
Human Genome Sciences, Inc., Key Competitors
Human Genome Sciences, Inc., Ratios based on current share price
Human Genome Sciences, Inc., Annual Ratios
Human Genome Sciences, Inc., Interim Ratios
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Human Genome Sciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Human Genome Sciences, Inc., Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Pipeline Products by Development Phase
Human Genome Sciences, Inc., Performance Chart (2006 - 2010)
Human Genome Sciences, Inc., Ratio Charts
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

Depomed, Inc.
PriceSpective Ltd.
AMN Healthcare Services, Inc.
AmSurg Corp.
IMMUNOMEDICS, INC
GlaxoSmithKline plc
Amgen Inc.
Novartis AG
ZymoGenetics, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS